Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
NEUROLOGIX INC (NRGX) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/16/2016 SC 13D/A Medtronic plc reports a 7.3% stake in Neurologix, Inc.
02/21/2013 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
03/22/2012 8-K Quarterly results
03/21/2012 8-K Form 8-K - Current report
02/16/2012 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Limited Engagement Agreement, entered into by the Company on February 14, 2012, by and between the Company and Global Resource Partners, Inc"
02/14/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/27/2012 8-K Form 8-K - Current report
12/21/2011 8-K Form 8-K - Current report
11/30/2011 8-K Form 8-K - Current report
11/15/2011 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB
10/31/2011 8-K Form 8-K - Current report
10/20/2011 DEF 14C Form DEF 14C - Other definitive information statements:
10/18/2011 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Docs: "Certificate of Amendment of Restated Certificate of Incorporation of Neurologix, Inc., filed with the Secretary of State of the State of Delaware on October 14, 2011"
10/18/2011 PRER14C Form PRER14C - Information statements
09/27/2011 SC 13D NEUROLOGIX INC reports a 6.2% stake in Neurologix, Inc.
09/27/2011 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Letter Agreement dated September 26, 2011, by and between Neurologix, Inc. and Dr. Matthew J. During"
09/27/2011 DEF 14A Form DEF 14A - Other definitive proxy statements
09/20/2011 4 ADAMS ADRIAN (CEO, CHAIRMAN OF THE BOARD) has filed a Form 4 on NEUROLOGIX INC/DE
Txns: Granted 7,420,063 options to buy @ $0.5, valued at $3.7M
09/20/2011 3 ADAMS ADRIAN (CEO, CHAIRMAN OF THE BOARD) has filed a Form 3 on NEUROLOGIX INC/DE
09/20/2011 4 KOVEN ANDREW I (See Remarks) has filed a Form 4 on NEUROLOGIX INC/DE
Txns: Granted 4,946,709 options to buy @ $0.5, valued at $2.5M
09/20/2011 3 KOVEN ANDREW I (See Remarks) has filed a Form 3 on NEUROLOGIX INC/DE
09/20/2011 8-K Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce...
Docs: "Amendment to Amended and Restated By-Laws of Neurologix, Inc., effective September 19, 2011",
"Executive Employment Agreement between Adrian Adams and Neurologix, Inc.",
"Executive Employment Agreement between Andrew I. Koven and Neurologix, Inc.",
"Stand-Alone Stock Option Agreement between Adrian Adams and Neurologix, Inc.",
"Stand-Alone Stock Option Agreement between Andrew I. Koven and Neurologix, Inc.",
"Press release of Neurologix, Inc."
09/15/2011 PRE 14A Form PRE 14A - Other preliminary proxy statements
08/11/2011 10-Q Quarterly Report for the period ended June 30, 2011
08/11/2011 8-K Quarterly results
Docs: "NEUROLOGIX, INC. BALANCE SHEETS June 30, 2011 December 31, 2010 ASSETS Current assets: Cash and cash equivalents $ 3,453 $ 8,055 Prepaid expenses and other current assets 319 481 Total current assets 3,772 8,536 Equipment, less accumulated depreciation of $704 and $682 at June 30, 2011 and December 31, 2010, respectively 49 71 Intangible assets, less accumulated amortization of $426 and $364 at June 30, 2011 and December 31, 2010, respectively 1,137 1,065 Other assets 5 5 Total assets $ 4,963 $ 9,677 LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities: Accounts payable and accrued expenses $ 3,375 $ 2,302 Notes payable, net of discount 6,078 4,695 Total current liabilities 9,453 6,997 Derivative financial instruments, at estimated fair value – warrants 4,174 6,840 Total liabilities $..."
08/04/2011 8-K Form 8-K - Current report
06/08/2011 8-K Form 8-K - Current report
05/26/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Slides related to one-year efficacy results of Neurologix, Inc’s Phase 2 trial for Parkinson’s disease (furnished pursuant to Item 7.01 of Form 8-K)",
"NEUROLOGIX PRESENTS ONE-YEAR FOLLOW-UP DATA FROM PHASE 2 STUDY OF NLX-P101 IN PARKINSON’S DISEASE AT INTERNATIONAL NEUROMODULATION SOCIETY 10th WORLD CONGRESS"
05/13/2011 8-K Submission of Matters to a Vote of Security Holders
05/13/2011 10-Q Quarterly Report for the period ended March 31, 2011
05/13/2011 8-K Quarterly results
Docs: "Neurologix Announces First Quarter 2011 Financial Results Fort Lee, New Jersey ? Neurologix, Inc. , a biotechnology company engaged in the development of innovative gene therapies for disorders of the brain and central nervous system, today announced its financial results for the three months ended March 31, 2011."
05/11/2011 4 KAPLITT MARTIN J DR (Director) has filed a Form 4 on NEUROLOGIX INC/DE
Txns: Granted 75,000 options to buy @ $0.8, valued at $60k
05/11/2011 4 HARDY REGINALD L (Director) has filed a Form 4 on NEUROLOGIX INC/DE
Txns: Granted 75,000 options to buy @ $0.8, valued at $60k
05/11/2011 4 PANOFF MARC L (CFO, TREASURER & SECRETARY) has filed a Form 4 on NEUROLOGIX INC/DE
Txns: Granted 150,000 options to buy @ $0.8, valued at $120k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy